Miansegen (Mianserin Hydrochloride)

Mianserin blocks central α2‑adrenergic receptors and antagonizes histamine H1, serotonin 5‑HT2 and 5‑HT3 receptors. This results in increased noradrenergic and serotonergic neurotransmission, producing an overall antidepressant effect without directly stimulating those pathways.

The appropriate dose of Miansegen is determined by the prescribing clinician based on the patient’s clinical condition, response, and tolerability. Dosage regimens are individualized and should follow the prescriber’s instructions.

Safety data for Mianserin in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Miansegen. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Mianserin, a tetracyclic antidepressant, differs from selective serotonin reuptake inhibitors (SSRIs) by its broader receptor profile, including α2‑adrenergic antagonism and antihistaminic activity. This can lead to distinct side‑effect patterns such as sedation and weight gain, while SSRIs typically have fewer anticholinergic effects but may cause sexual dysfunction.

Store Miansegen at room temperature, below 25 °C, in the original packaging. Protect the tablets from moisture, excessive heat, and direct sunlight to maintain potency and stability throughout its shelf life.

Miansegen is taken orally as a tablet, usually with a glass of water. It is commonly administered once daily, but the exact schedule should follow the prescribing clinician’s directions.

Serious adverse reactions include agranulocytosis, seizures, severe hypotension, cardiac arrhythmias, hepatotoxicity, and neuroleptic malignant‑like syndrome. Patients should be monitored regularly for signs of these conditions, and any concerning symptoms should prompt immediate medical evaluation.

Miansegen should be avoided in individuals with known hypersensitivity to Mianserin or any excipients, those currently taking monoamine oxidase inhibitors, patients with severe hepatic impairment, and anyone with a history of agranulocytosis or uncontrolled cardiac arrhythmias.